Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERVIEW: Clinuvel's Philippe Wolgen on Scenesse and the patient factor

This article was originally published in Scrip

Executive Summary

Not many pharmaceutical executives would take credit for helping to steer the European Medicines Agency in a particular direction when it comes to assessing new innovative medicines. But that's what Philippe Wolgen, CEO of the Australian rare diseases company Clinuvel, claims to have achieved when he decided to seek EU approval for the ground-breaking phototoxicity drug Scenesse with the close involvement of patients and physicians.

You may also be interested in...



Interview: Clinuvel, A Company That Does The Unusual

“There will be one price and no discounts, no backroom deals, no incentives off the record.” In an interview with the Pink Sheet, Clinuvel UK’s general manager Lachlan Hay talked about the company’s unusual pricing policy for its equally unusual photoprotective therapy, Scenesse (afamelanotide), its frustrations at out-of-sync regulatory and market access systems, and how its plans for a US regulatory filing are going.

Dutch See First European Launch Of Clinuvel's Scenesse For Phototoxicity In EPP

Clinuvel is beginning the commercial launch in Europe of its orphan drug Scenesse for patients with erythropoietic protoporphyria, a rare condition that causes severe anaphylactic reactions and burns when the skin is exposed to sunlight.

And The UK's First 'Innovation Passport' Goes To... Merck's Rare Disease Drug Belzutifan

The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel